Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Thoracic 4CNS 4Lymphoid 3Head & Neck 3Gynecologic 3Other solid neoplasm 2Other hematologic neoplasm 2Other 2Sarcoma 1Myeloid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Liver Neoplasms 1Hearing Loss 1

Interventions

Radiotherapy 215Cyclophosphamide 210Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Irinotecan 79Magnetic Resonance Spectroscopy 78pembrolizumab 75Radiation 66Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 44Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Acetylcysteine × Sarcoma × Clear all
NCT02094625 2023-04-18

NAC to Prevent Cisplatin-induced Hearing Loss

Children's Hospital Los Angeles

Phase 1 Completed
52 enrolled
GastrointestinalSarcoma

Liver Neoplasms, Osteosarcoma, Neuroectodermal Tumors, Primitive, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡